- Home
- TXO vs QURE Comparison
TXO vs QURE Comparison
Compare TXO & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXO | QURE |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.7M | 663.4M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TXO | QURE |
|---|---|---|
| Price | $12.75 | $16.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $20.50 | ★ $45.42 |
| AVG Volume (30 Days) | 199.9K | ★ 4.5M |
| Earning Date | 04-30-2026 | 03-02-2026 |
| Dividend Yield | ★ 13.62% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $401,012,000.00 | $13,107,000.00 |
| Revenue This Year | $15.64 | $126.14 |
| Revenue Next Year | N/A | $395.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.80 | N/A |
| 52 Week Low | $10.12 | $7.76 |
| 52 Week High | $19.99 | $71.50 |
Technical Indicators
Market Signals| Indicator | TXO | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 44.40 |
| Support Level | $12.50 | $13.19 |
| Resistance Level | $12.94 | $16.62 |
| Average True Range (ATR) | 0.34 | 1.72 |
| MACD | -0.03 | 0.28 |
| Stochastic Oscillator | 61.32 | 66.30 |
Price Performance
Historical ComparisonAbout TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.